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Summary The development of familial and sporadic breast cancer is based on genetic alterations of tumour-
suppressor genes, for which loss ofheterozygosity (LOH) is one mechanism ofgene inactivation. To investigate
LOH ofBRCAJ (17q21) and BRCA2 (13ql2- 13) in sporadic breast cancer, polymerase chain reaction (PCR)-
based fluorescent DNA technology for detection of microsatellite polymorphisms was applied. A total of 137
breast cancer and 15 benign breast specimens with matched normal tissue were examined. Fluorescent-labelled
PCR products were analysed in an automated DNA sequencer (ALFTM Pharmacia). Losses at both loci were
correlated with different histological types, age, tumour size, lymph node status, grading and steroid hormone
receptor expression, [SHR: oestrogen receptor (ER), progesterone receptor (PgR)]. For BRCAI (D17S855,
THRAI, D17S579) losses could be detected in invasive ductal carcinoma (IDC; n= 108) in 32-38%, invasive
lobular carcinoma (ILC; n = 19) in 21-42% depending on the marker applied, but not in benign breast
tumours (n = 15). Losses of BRCAI markers correlated with larger tumour size, higher grade, and PgR
expression. For BRCA2 (D13S260, D13S267, D13S171) losses could be detected in 108 IDCs in 30-38%, in 19
ILCs in 17-39% depending on the marker applied, but not in benign breast tumours. Losses of BRCA2
markers correlated only with higher grade.
Microsatellite analyses combined with detection of fluorescent-labelled PCR products by an automated laser
DNA sequencer can be used for routine determination of LOH. In sporadic breast cancer, LOH of BRCAI or
BRCA2 does not add decisive prognostic value as stated for familial breast cancer.
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Cytogenetic and molecular genetic analysis of breast cancer
samples suggest that the development of human breast cancer
is based on the accumulation of various genetic alterations,
including activation of oncogenes as well as inactivation of
tumour-suppressor genes (Black, 1994; El-Ashry and
Lippmann, 1994). Loss of normal tumour-suppressor protein
function can occur through sequential gene mutation events
(somatic alteration) or through a single mutational event of a
remaining normal copy when a germline mutation is present.
In inherited cancer this second event uncovers the constitu-
tional recessive mutation. The second event is usually
chromosome loss, mitotic recombination or partial chromo-
some deletion. A hallmark of the involvement of a tumour
suppressor-gene in cancer development may be allelic loss in
tumour DNA. Loss of heterozygosity (LOH) has been
observed for several loci (lq, lp, 3p, 6q, 7q, lip, llq, 13q,
16q, 17p, and 17q) in familial and sporadic breast cancer with
frequencies ranging between approximately 20% and 79%
(Sato et al., 1990; Andersen et al., 1992; Chen et al., 1992;
Futreal et al., 1992; Kirchweger et al., 1994; Wooster et al.,
1994; Collins et al., 1995).
Assessment of allelic loss of tumour-suppressor genes has
been limited by the position and frequency of heterozygosity
in instances where classical restriction length polymorphisms
(RFLPs) are used. Because of their abundance, polymorphic
nature and amenability to amplification by polymerase chain
reaction (PCR), short tandem repeats (STRs) are much better
markers for genomic mapping and genetic linkage analysis.
STRs provide a source of highly informative loci for use in
identification of individual allele patterns. The ability to
resolve PCR products differing in size by just one base on
polyacrylamide gels allows precise allele designation, even
though enzyme slippage during amplification may result in
artificial stutter bands. Thus, the ability to amplify multiple
loci using different fluorescent primers in a single reaction
coupled with direct detection of the fluorescent-labelled,
amplified products on polyacrylamide gels makes STR DNA
profiling amenable to automated fluorescent DNA technol-
ogy.
Lately, two genes, BRCAJ, located on chromosome
17q21 (Hall et al., 1992; Easton et al., 1993; Miki et al.,
1994; Futreal et al., 1994) and BRCA2, located on 13qI2-
13 (Wooster et al., 1995), having been shown to be involved
in familial breast and ovarian cancer. A third gene, the
ataxia telangiectasia (AT) gene, may also contribute
significantly to the development of hereditary breast
cancer. Heterozygous carriers of the mutated gene (ATM)
are at significantly increased risk owing to altered response
to DNA damage and increased radiation sensitivity.
However, ATM study data are still rare (Savitsky et al.,
1995). To date, in familial breast cancer, BRCAI mutations
account for 45% and BRCA2 mutations for 40% of cases;
in familial breast/ovarian cancer families BRCAJ mutations
account for 80% of cases. Analysis of these BRCAI families
has revealed individual risks of >90% and 44% of
developing breast and ovarian cancer by the age of 80
respectively (Easton et al., 1993; Ford et al., 1994).
Concerning the BRCAJ gene, 80 mutations have been
described (Futreal et al., 1994; Shattuck-Eidens et al.,
1995) using single-strand conformation polymorphism
(SSCP) analysis on PCR-amplified genomic DNA or direct
sequencing. The heterogeneity of mutations, coupled with
the large size of the gene, indicate that routine clinical
application of BRCAJ mutation testing is technically
challenging (Boyd, 1995; Hogervorst et al., 1995; Shattuck-
Eidens et al., 1995). Therefore, allelotyping of high-risk
breast/ovarian cancer families including detection of LOH in
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tumour samples of affected relatives and linkage analysis of
pedigree data is still a useful method for identifying BRCAI
and/or BRCA2 carriers. Their key role in the development
of familial breast cancer suggests an involvement of these
two genes in sporadic breast cancer. To gain insight into the
putative role of BRCAI and BRCA2 in tumour biology of
sporadic breast cancer, LOH of these two genes was
analysed. A routine technique based on PCR amplification
of STRs and fluorescent DNA technology was applied and
validated. LOH data were correlated with clinical para-
meters such as patients' age, histopathological findings, and
steroid hormone receptor expression to evaluate the clinical
potential of detection of these genetic alterations.
Materials and methods
Materials
Snap-frozen samples (-80°C) from 15 patients with benign
breast tumours and samples from 137 patients (from October
1992 to the present) treated with surgery for primary breast
cancer [108 invasive ductal carcinoma (IDC), 19 invasive
lobular carcinoma (ILC) and ten other invasive breast
cancers (two medullar, three mucinous, five tubular)] were
analysed. All patients with breast cancer underwent axillary
dissection (at least ten lymph nodes) to determine the number
of lymph node metastases. None of the patients received
neoadjuvant treatment or had distant metastases at the time
of primary surgery. Haematoxylin-eosin staining was used
for routine pathological evaluation (diameter, margins,
grading, histological typing). Oestrogen receptor (ER) and
progesterone receptor (PgR) expression were determined by
immunohistochemistry and scored as described previously
(Beckmann et al., 1994). As a source of normal DNA for
analysis of loss of heterozygosity (LOH) either peripheral
blood leucocytes, which were obtained from patients at time
of surgery, or sections of lymph nodes without tumour
infiltration (evaluation of serial sections under light micro-
scopy by pathologist) were used. For the detection of LOH in
a specific tumour sample the amount of tumour cells should
exceed at least 60%, otherwise the decrease in signal intensity
is too weak to be detected and leads to a false-negative result.
In preliminary experiments, the quality of DNA extracted
from haematoxylin-eosin-stained sections was checked and
compared with toluidine staining, another staining method
frequently used. There was no difference in PCR results
between both staining methods. Sections from routine
pathological staining can therefore be used for molecular
genetic analysis. Results were correlated with menopausal
status, tumour size, number of lymph node metastases,
histologic grading and ER or PgR expression.
DNA extraction
Genomic DNA from peripheral blood leucocytes was
prepared by a standard protocol (Ausubel et al., 1994).
Briefly, pellets ofwhite blood cells were dispersed in Tris-HCl
buffer (100 mM, pH 7.5) containing 0.5% sodium dodecyl
sulphate (SDS) and digested with proteinase K (100 Mg ml-1)
for 3 h at 45°C. After repeated extractions (phenol-
chloroform-isoamylalcohol, 25:24:1) high molecular weight
genomic DNA was precipitated with salt-ethanol at -20°C
for 2 h and dissolved in double-distilled water. Tumour DNA
was extracted from tissue samples adjacent to a haematox-
ylin-eosin-stained section (5 gm) assessed for pathological
diagnosis and tumour content (Shibata, 1994). Frozen tissue
samples were pulverised using a microdismembrator (Braun
Melsungen, Germany) and dispersed in proteinase K
digestion buffer (100 mM Tris-HCl pH 8.5, 1 mM EDTA,
0.5% SDS) with 100 Mg ml-1 proteinase K (Boehringer,
Mannheim, Germany). After incubation for 12-16 h at
50°C samples were heated at 95°C for 10 min to inactivate
proteinase K. This was followed by two extractions with
phenol-chloroform-isoamylalcohol (25:24:1) and one with
chloroform-isoamylalcohol (24:1). After ethanol -salt pre-
cipitation at -20°C DNA was spun, dried and resuspended
in ddH2O. DNA was quantitated on a lambdaBio spectro-
photometer (Perkin Elmer, Uberlingen, Germany).
Primers and loci analysed
Primer sequences of BRCAJ markers (D17S855, THRAl,
D17S579) and of BRCA2 markers (D13S171, D13S260,
D13S267) used for amplification of STRs were available
from GenomeDataBase (GDB), Johns Hopkins Welch
Library, Johns Hopkins University, Baltimore, MD, USA.
The primers were purchased from PharmaciaBiotech






CTCAG, 5'-TAGGGCCATCCATTCT), D13S260 (5'-F-AG
ATATTGTCTCCGTTCCATGA, 5'-CCCAGATATAAGG
ACCTGGCTA), and D13S267 (5'-F-GGCCTGAAAGG-
TATCCTC, 5'-TCCCACCATAAGCACAAG). One primer
of each primer pair was fluorescein-labelled (F) at the 5'end,
all primers were purified through NAP 10 columns and
stored at -20°C.
PCR reaction andfluorescent labelling
The target sequences were amplified by PCR in 50 Ml of
1 x Taq polymerase reaction buffer containing 40 pmol of
each primer, 1.5 mm magnesium chloride, 100-125 gM each
of dATP, dCTP, dGTP, dTTP, 2.5 units of Taq polymerase
(Pharmacia Biotech) and 20-50 ng of genomic DNA. The
reaction mixture was overlaid with mineral oil. The reaction
was started after 5 min denaturation of DNA at 94°C (hot
start). DNA amplification in a TC486 (Perkin Elmer,
Weiterstadt, Germany) or Omnigene thermal cycler (Hy-
baid, Teddington, UK) was followed by a final extension for
8 min at 72°C for THRAl (94°C 1 min, 55°C 2 min, 72°C
1 min; 27 cycles), D17S855 (94°C 1 min, 55°C 1 min, 72°C
1 min; 30 cycles), D17S579 (94°C 1 min, 55°C 1 min, 72°C
1 min; 27 cycles), D13S260 (94°C 1 min, 58°C 1 min, 72°C
1 min; 30 cycles), D13S267 (94°C 1 min, 55°C 2 min, 72°C
1 min; 27 cycles), D13S171 (94°C 1 min, 50°C 1 min, 72°C
1 min, 32 cycles).
PCRfragment analysis
PCR amplification products were analysed on 6% polyacryla-
midedenaturing gels in 0.6 x TBE bufferin an automated laser-
activated fluorescent DNA sequencer (ALF, Pharmacia
Biotech). Diluted PCR reaction mixture (5 Ml) (1:20-1:80)
was mixed with 5 Ml of stop solution (90% formamide, 10 mM
EDTA, 0.3% bromophenol blue) containing a fluorescent-
labelled fragment of defined size as internal loading control.
The mix was denatured at 95°C for 5 min, cooled on ice, loaded
into a well on the preheated gel (40°C), and run for 3-4 h at
30W 4mA. While the samples were undergoingelectrophoresis,
fluorescence was detected after laser activation. Data were
collected automatically during electrophoresis and calculated
using Fragment Manager (FM1.1) software (Pharmacia
Biotech), which yields quantitation of results in terms of peak
size, height and area under the curve.
Assessment ofallelic loss
In heterozygous individuals two alleles, i.e. two PCR
products of different size, can be detected in normal DNA.
The sizes of two alleles were assigned to the peaks of greatest
height following smaller peaks, which were interpreted as
polymerase artefacts, so-called stutter bands. Because PCR
fragments of different sizes are amplified with different
efficiencies, the ratio of allele peak areas was calculated byLOH of BRCA1 and BRCA2 in sporadic breast cancer
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comparing matched normal and tumour DNA samples. Peak
areas of the larger length alleles were divided by the peak
areas of the shorter length allele. The ratio obtained in
tumour DNA divided by the allele peaks ratio of matched
normal DNA has a mathematical range of 0.00- 1.00.
Theoretically, a complete allele loss in tumour tissue results
in a value of0.00, retention of both alleles in both tissues in a
ratio of 1.00 (Sato et al., 1990; Lubin et al., 1991). When the
shorter length allele is lost in tumour DNA this results in an
allele peaks' ratio greater than 1.00. For unification of
mathematical results, this allele peaks' ratio was converted
(1/x) to obtain values below 1.00. An allele peaks' ratio
below 0.6, indicating an allele signal reduction of 40%, was
considered to be an allele loss.
Statistical methods
Associations of LOH with other clinicopathological factors
were calculated by the chi-square test. The statistical analyses
were performed using the BIAS statistical package (H
Ackkermann, Institute of Biostatistics, University of Frank-
furt, 1994).
Results
In DNA extracted from sections of a total of 137 primary
breast cancers and 15 benign breast tumours, LOH of three
BRCAJ markers (D17S855, THRAl, D17S579) and three
BRCA2 markers (D13S260, D13S267, D13S171) was
analysed. All analyses were performed twice, and the mean
LOH value calculated. Various groups have defined LOH as
a signal reduction of at least 40% (Chen et al., 1992;
Kirchweger et al., 1994; Niederacher et al., 1996). In
instances when the signal reduction was close to this cut-off
value, PCRs were repeated twice and thereafter the mean
value of the four reactions calculated. As regards the
percentage of signal reduction for each marker, less than
6% of the tumours had borderline values (40+10%).
To establish conditions for detection of LOH of various
BRCAI and BRCA2 markers, fluorescent PCR (fPCR) using
primers flanking STR regions was applied. PCR was
optimised in terms of amplimers, enzyme concentration and
cycle number. For determination ofexact allele sizes an allelic
ladder was constructed by combining PCRs deriving from
DNAs of different patients having different heterozygous
allelic patterns. The allelic ladder encompassed all known
alleles. An exact assignment of both alleles of each patient or
of each tumour sample was feasible. During each electro-
phoretic separation one lane was reserved for an aliquot of
this allele mixture (Figure 1) and, together with the internal
size marker in the sample buffer, lane to lane variations were
excluded.
For BRCAJ markers (Table I) losses could be detected in
IDC in 32-38%, in ILC in 21-42%, in other invasive breast
tumours in 29-43% of cases, but not in benign breast
tumours. Associations between LOH in IDC and patient's
age or histological characteristics were determined (Table II).
In IDC, losses of BRCAJ markers correlated significantly
with larger tumour size (D17S855: overall P= 0.023, TI vs T2
P=0.02; THRAl: P=0.007, T2 vs T3 P=0.004), higher
grade (D17S855: overall P=0.0036, GI vs G3 P=0.017, G2
125 130 135 140 145 150 155 160 165
Figure 1 Print-out from the automated DNA sequencer of various DNA probes analysed with internal BRCAJ marker D17S855.
The x-axis shows size in bp. In each lane the internal size marker of 136bp (green marking) is added. Lane 11, allele mixture
encompassing eight alleles (dinucleotide repeats) from 140bp to 154bp (green marking); lane 30, DNA extracted from lymphocytes
of patient no. 11, result: heterozygous, allele 144bp/154bp; lane 28; DNA extracted from lymphocytes of patient no. 16, result:
homozygous, allele 152bp; lane 24, DNA extracted from lymph node of patient no. 20, result: heterozygous, allele 142bp/152bp;
lane 25, DNA extracted from breast tumour of patient no. 20, result: heterozygous, allele 152bp shows 83% signal reduction
compared with the allele 152bp in non-tumour tissue (lane 24).
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Table I Overall rates of LOH in three BRCAI and in three BRCA2 marker regions analysed in invasive ductal carcinoma (IDC), in invasive
lobular carcinoma (ILC), in other invasive types of breast carcinoma and in benign breast tumours (n= 152)
Number
Histological typing (n= 152) D17S855 THRA1 D17S579 D13S260 D13S267 D13S271
IDC 108 37.0% 37.5%/o 32.1% 30.4% 34.8% 36.4%
ILC 19 21.4% 41.7% 37.5% 16.7% 38.5% 20.0%
Other types of invasive 10 28.6% 42.9% 37.5% 33.3% 14.2% 0%
breast carcinoma
Benign breast tumours 15 0% 0% 0% 0% 0% 0%





Criteria n= 108 ND NI LOH LOH P ND NI LOH LOH P ND NI LOH LOH P
Age
<50 33 1 6 10 16 3 8 7 15 2 6 8 17
>50 75 7 12 21 35 P=0.870 15 10 20 30 P=0.690 10 12 17 36 P=0.800
Tumour
TI 57 5 8 11 33 10 9 8 30 6 5 11 35
T2 40 3 9 16 12 P=0.023 7 6 16 11 P=0.007 6 10 12 12 P =0.077
T3/4 11 0 1 4 6 1 3 3 4 0 3 2 6
Nodes
NO 54 5 8 17 24 13 6 14 21 7 7 14 26
N1/2 54 3 10 14 27 P=0.648 5 12 13 24 P=0.86 5 11 11 27 P=0.740
Grade
I 14 2 4 1 7 5 1 1 7 4 1 0 9
II 64 4 11 14 35 P=0.036 9 9 14 32 P=0.08 5 8 18 33 P=0.087
III 30 2 3 16 9 4 8 12 6 3 9 7 11
ND, not determined; NI, not informative; LOH, loss ofheterozygosity; P, overall P-value.





Criteria n= 108 ND NI LOH LOH P ND NI LOH LOH P ND NI LOH LOH P
Age
<50 33 2 3 6 22 2 7 7 17 18 6 1 8
50 75 22 11 15 27 P=0.31 13 17 17 28 P=0.65 53 9 7 6 P=0.074
Tumour
T1 57 12 6 10 29 7 14 12 25 38 9 3 7
T2 40 10 7 9 14 P=0.50 6 8 9 16 P=0.85 27 4 4 5 P=0.80
T3/4 11 2 1 2 6 2 2 3 4 6 2 1 2
Nodes
NO 54 8 7 13 26 7 10 13 24 32 9 5 8
N1/2 54 16 7 8 23 P=0.67 8 14 11 21 P=0.85 39 6 3 6 P= 1.0
Grade
I 14 1 2 3 8 3 3 0 8 11 2 0 1
II 64 17 8 10 29 P=0.51 8 16 14 26 P=0.055 41 10 4 9 P=0.495
III 30 6 4 8 12 4 5 10 11 19 3 4 4
ND, not determined; NI, not informative; LOH, loss ofheterozygosity; P, overall P-value.
vs G3 P=0.005; THRAI: overall P=0.008, GI vs G3
P=0.05, G2 vs G3 P=0.011), but not with age and lymph
node status. For BRCA2 markers (Table I) losses could be
detected in IDC in 30-31%, in ILC in 17-39%, in other
invasive breast tumours in 0-33% ofcases, but not in benign
breast tumours. Only losses of BRCA2 marker D13S267 in
IDC (Table III) correlated significantly with higher grade
(overall P=0.055, GI vs G3 P=0.026). There was no
correlation with age, tumour size, and lymph node status.
Owing to low numbers, losses ofBRCAJ and BRCA2 in ILC
and other subgroups were not analysed by statistical tests.
To improve genetic information about the individual
tumours, losses of all six markers on both chromosomes
were combined (Table IV) and analysed in IDC and ILC. In
IDC and ILC, cases with exclusive losses of BRCAJ were
twice as abundant as those of exclusive losses of BRCA2. In
IDC for exclusive losses of BRCAJ statistical significances
compared with the group without losses were seen for tumour
size (overall P=0.074, TI vs T2 P=0.01), for tumour grade
(overall P=0.02, GI vs G3 P=0.018), but not for age and
lymph node metastases. Exclusive losses of BRCA2 did not
correlate significantly with any of the parameters analysed.
Combination of losses of BRCAI and BRCA2 revealed
significant relationships for tumour size (overall P=0.04, TI
vs T2 P=0.04) and tumour grade (overall P=0.01, GI vs G3
P=0.03, G2 vs G3 P=0.016) but not for age and lymph
node metastases.
For all tumour samples data for steroid hormone receptor
(SHR) expression were available. 65% of the tumours were
PgR, 63% ER positive. In none of the histological subgroups
did ER expression correlate significantly with loss of BRCAI
or BRCA2. For PgR expression, there was a significantLOH of BRCA1 and BRCA2 in sporadic breast cancer
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Table IV Number of LOH at BRCAl or/and BRCA2 loci of invasive ductal (n= 108) and invasive lobular (n= 19) carcinoma correlated with
patient's age and histopathological findings (n total= 127)
LOH at two
Not informative No LOH LOH at BRCA1 LOH at BRCA2 chromosomes
IDC ILC Total IDC ILC IDC ILC IDC ILC IDC ILC IDC ILC
Criteria 108 19 127 (n =6) 0 (n=41) (n =8) (n =21) (n=5) (n =12) (n =2) (n =23) (n=4)
Age
<50 33 6 39 1 0 13 3 7 1 2 0 7 2
50 75 13 86 5 0 28 5 14 4 10 2 16 2
Tumour
Ti 57 9 66 2 0 26 4 7 2 8 1 9 2
T2 40 8 48 3 0 9 2 13 3 4 1 11 2
T3/4 11 2 13 1 0 6 1 1 0 0 0 3 0
Nodes
NO 54 7 61 4 0 20 4 9 1 4 1 16 1
N1/2 54 12 66 2 0 21 4 12 4 8 1 7 3
Grade
I 14 14 1 7 0 1 1
II 64 64 2 28 13 9 11
III 30 30 3 6 8 2 11
X 19 19 0 8 5 2 4
inverse correlation in IDC with all three BRCAI markers, but
none with the three BRCA2 markers. Combining LOH data
of both loci and comparing them with SHR expression
showed significant correlations for PgR, but not for ER.
Discussion
Breast cancer occurs in hereditary and sporadic forms and
shows clinical and genetic heterogeneity. Clinically, the onset
of breast cancer at an early age, an excess of bilaterality and
patterns of multiple primary cancers such as combinations of
breast and ovarian cancers point to a hereditary breast-
ovarian cancer syndrome (Lynch et al., 1994). In 1990 an
autosomal dominant susceptibility gene for breast and
ovarian cancer, BRCAI, was assigned to chromosome
17q21 by multipoint genetic linkage (Hall et al., 1990
Albertsen et al., 1994) and was later cloned and sequenced
(Miki et al., 1994). Observations of LOH for polymorphic
markers widely spaced along chromosome 17q (Futreal et al.,
1992; Hall et al., 1992; Easton et al., 1993; Knyazev et al.,
1993; Kirchweger et al., 1994; Lalle et al., 1994) have led to
the hypothesis that BRCAJ is a tumour-suppressor gene.
According to Knudson's model of a tumour-suppressor gene,
functional loss of both alleles in breast or ovarian tissues is
necessary for malignant transformation to occur. In a familial
background a germline mutation is the first step in gene
inactivation; for sporadic breast cancer a somatic mutation is
supposed to happen. A total of 38 distinct mutations were
found among 63 mutations identified through a complete
screening of the BRCAI gene in 372 patients from high-risk
families (Shattuck-Eidens et al., 1995). Up to the present
time, in sporadic breast cancer no BRCAJ mutations have
been found, even though somatic mutations could be detected
in the coding regions ofBRCAJ in sporadic ovarian tumours
(Hosking et al., 1995; Merajver et al., 1995). However, it is
thought that the BRCAJ gene is important in the aetiology of
sporadic breast cancer. Indirectly, this hypothesis is
supported by a report (Thompson et al., 1995) that
transcription of BRCAJ mRNA varies through progression
of breast cancer. Normal breast tissue expresses BRCAI
mRNA at higher levels than ductal carcinoma in situ (DCIS)
or IDC. In culture, experimental inhibition of BRCAI
mRNA expression with antisense oligonucleotides acceler-
ated growth of normal and malignant mammary cells. These
studies imply that BRCAI may function as a negative
regulator of mammary epithelial cell growth whose function
is altered either through mutation or LOH.
Although routine BRCAJ sequencing for point mutations
is not practicable technically, the detection of truncated
proteins encoded by BRCAJ mutations is under investigation
(Hogervorst et al., 1995). In addition, the sequence of
BRCA2 has been published only very recently (Wooster et
al., 1995). For a clinical setting, detection of LOH in various
genetic markers of BRCAJ and BRCA2 in tumours may
therefore be the most appropriate starting point to gain
information about tumour biology or individual prognosis.
In this study, the routine application of PCR and fluorescent
DNA technology for detection of LOH was therefore
validated and tested. Microsatellite polymorphisms detecting
differences in STR sequences were amplified by fluorescent
PCR and analysed in an automated DNA sequencer (Liu et
al., 1993; Niederacher et al., 1996). The combination of both
methods offers several advantages compared with other
staining methods and autoradiography:
(1) It is much faster than Southern blot or radioactive
PCR. Separation and direct quantification of PCR products
can be performed automatically and requires approximately
3 h without additional staining steps. This allows quantifica-
tion of as many as 40 individual samples simultaneously and
2-3 gels per day to be run on a routine basis.
(2) Fluorescent-labelled primers and PCR products can
be stored, as labelling for both primers and products is stable
for several months at -20°C.
(3) The enhanced sensitivity of the fluorescent detection
method required 25-30 PCR cycles only to achieve
detectable results. Linearity of fluorescence detection covers
a much wider range than scanning of autoradiograms or
ethidium bromide- or silver-stained gels, resulting in
improved quality of data. Therefore, this approach is
particularly suitable for the analysis of large series of
samples and routine clinical use.
Various groups have analysed LOH at chromosomal
region 17q close to the BRCAJ locus, for example, Futreal
et al. (1992; THRAI, D17S579), Knyazev et al. (1993; THH-
59), Cropp et al. (1993; 19 polymorphic markers) or
Kirchweger et al. (1994; AFMl55xdl2, AFM234td2), but
very few studies used the intragenic markers D17S855 or
D17S1323 (Futreal et al., 1994; Albertsen et al., 1994). These
studies did not intend primarily to use the detection of LOH
for clinical purposes, but to focus on the localisation of
potential breast cancer candidate genes. Therefore, the
number of cases analysed were small (14-55) and correla-
tions with clinical parameters were not extensive. In this
study, we intended to obtain clinical information from the
detection ofLOH ofBRCAI. For LOH ofthe BRCAJ region
three different markers, one intragenic (D17S855) and two
extragenic markers (THRAI, D17S579), were tested. In IDC,
overall rates of LOH varied from 32% to 37% without
significant differences between intragenic and extragenic
markers. For ILC and other types of invasive breast
carcinoma these rates extend from 21-28 to 41-43%. ForLOH of BRCA1 and BRCA2 in sporadic breast cancer
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ILC this revealed a difference between the intragenic
D17S855 and the extragenic THRAI and D17S579
markers; for other types of invasive breast carcinoma the
data were too few in number for statistical analysis. Other
studies (Futreal et al., 1992; Knyazev et al., 1993; Kirchweger
et al., 1994) have reported 29-79% of LOH, but no
differences between tumour types have been stated. This
should be taken into consideration when comparing LOH
data from different studies. For example for IDC, our data
are similar to those by the Kirchweger group, but the data
for ILC vary significantly. This implies that: (1) the genetic
basis of tumorigenesis varies between different types of breast
tumours and (2) the use of a single extragenic marker to
characterise LOH of a specific tumour-suppressor gene is not
sufficient to obtain clinical information. In hereditary breast
cancer (Jacquemier et al., 1995), IDC is by far the most
abundant tumour type (below age 40: 100%) and 100% of
these tumours are histological grade 3. Grade 3 indicates
poor prognosis and implies that BRCAI-associated breast
cancer is worse than sporadic breast cancer. Here, in sporadic
IDC, LOH of BRCAJ markers correlated with larger
tumours and likewise higher grade. Survival data are not
available at the moment, but will show in the future whether
LOH of BRCAJ markers independently indicates decreased
survival.
LOH data for BRCA2 in breast tumours are scanty.
Andersen et al. (1992) and Deng et al. (1994) found LOH in
20-46% of sporadic breast tumours, Collins et al. (1995) in
88% of familial breast cancers. Anderson et al. (1992)
differentiated varieties of histological types and stated that
LOH of BRCA2 markers was present only in IDC. In our
study, we could detect LOH of BRCA2 markers not only in
IDC (30%), but also in 14-38% in ILC and other types of
invasive breast carcinoma. Nonetheless, these LOH rates in
sporadic breast cancers were far lower than the rates in breast
cancer families (Collins et al., 1995). As stated by Andersen
et al. (1992) none of the classical parameters correlated with
LOH. These findings and the fact that LOH of BRCA2 was
not as abundant as LOH ofBRCAJ indicate that loss of this
chromosomal region happens later in the cascade of genetic
events than the loss of the 17q region.
Up to now, a comparison of LOH of both chromosomal
regions, BRCAJ and BRCA2, in the same study population
has not been published. For all histological subgroups
analysed, LOH of BRCAI was a more abundant phenomen-
on than LOH of BRCA2. This could be explained by the
complexity of chromosome 17 with multiple potential targets
of LOH (e.g. TP53, HICJ, BRCAI, NMEI, MDC,
prohibitin) and overlapping regions of allelic losses. In
addition deletion patterns were often consistent with the
loss of a large portion of a chromosomal arm or even with
the complete loss ofchromosome 17 (Kirchweger et al., 1994;
Devilee and Cornelisse, 1994; Niederacher et al., 1996).
Exclusive LOH of BRCA1, as well as combined losses of
BRCAJ and BRCA2, always correlated significantly with
higher grade, as seen in familial histopathology (Jacquemier
et al., 1995). Tumour size, indicating rapid cellular
proliferation and division, seemed to be another variable,
that might correlate with alteration of BRCAI and BRCA2.
Genetic analyses by linkage and LOH at these specific
chromosomal regions implicates the presence of two tumour-
suppressor genes. However, it may be possible for LOH of
these genes to be randomly acquired and irrelevant to tumour
development. Other authors (Chen et al., 1992) have
demonstrated an overall 4% background incidence of LOH
calculated by LOH analysis of 12 randomly chosen
chromosomal regions (Chen et al., 1992). Devilee and
Cornelisse (1994) have compiled allelotype data from over
30 studies, comprising more than 1000 sporadic breast
tumour specimens. An incidence of LOH below 10% is
expected for LOH events unimportant for breast tumour
development, probably resulting from genetic instability
associated with tumour development and progression.
Incidences of LOH of BRCAI and BRCA2 in our study
were significantly greater than the arbitrary cut-off defined in
the compilation study (Devillee and Cornelisse, 1994),
indicating a possible role for BRCAI and BRCA2 in
sporadic breast cancer. Whether LOH of these genes is one
ofthe key steps in multistep carcinogenesis of sporadic breast
cancer and whether LOH analysis results in more relevant
prognostic information has to be verified in a larger study
group including earlier stages of sporadic breast cancer and
clinical follow-up. However, the LOH analysis of BRCAI
and BRCA2 by PCR and fluorescent DNA technology
proved to be feasible in the routine setting.
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